Ustekinumab shows promise for reducing psoriasis-associated cardiovascular comorbidity
|
Initial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018. |
Learn More.
|
|
From new vaccines to the advent of new neurotoxins
|
Physicians weigh in expectations for new developments within all facets of dermatology from pediatric dermatology to dermatopathology. |
Learn More.
|